What to Look For in Gilead Sciences Earnings Report
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.
Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Merck reported better-than-expected third-quarter earnings Monday morning.
Lakeland Industries announced that it entered into a definitive securities purchase agreement to raise $11.2 million in a private placement of common stock.
Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."
ThinkstockJust when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again. The location…
ThinkstockDoes Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech giant’s earnings. The company…
The following companies were featured in a new Leerink report on understand testing trends for sexually transmitted diseases.
24/7 Wall St. would ask if this turnaround in Boston Scientific earnings and outlook is really convincing investors.
A new research report from Merrill Lynch features three top pharmaceutical companies, dubbed the “Irish 3-Pack.”
Biogen Idec reported better-than-expected third-quarter results before the market opened Wednesday.
Amgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that is the case brought…